Stopping Zepbound, Wegovy or another GLP-1: what the labels say
The short answer
Stopping Zepbound: in the label's withdrawal trial, body weight rose 14.0% over 52 weeks in patients switched to placebo. In Wegovy's trial, it changed by +6.9% over 48 weeks. If you restart after a gap, the Wegovy label says to step up again from a lower dose after 2 or more missed weekly doses.
Key takeaways
- In Zepbound's Study 4, weight rose 14.0% over 52 weeks after patients switched to placebo.
- Wegovy, Ozempic and Rybelsus labels: stop at least 2 months before a planned pregnancy.
- Missed 2 or more Wegovy injections in a row? The label restarts the step-up at a lower dose.
- Saxenda: more than 3 days since your last dose means restarting at 0.6 mg daily.
- Off Zepbound, Mounjaro, Ozempic or Trulicity for more than one dose? Ask your prescriber before your next one.
People stop a GLP-1 for many reasons: cost, losing a prescription benefit, side effects, a planned pregnancy, surgery, or reaching a goal. The labels say less about stopping than about starting, but what they do say is specific. This page gathers it: when a label says to discontinue, what the labels’ trials measured afterward, and the rules for restarting.
None of it is advice to stop or to continue. If you’re thinking about coming off your medicine, or you’ve already run out, talk to your prescriber.
When do the labels say to stop?
The labels in our records name these situations.
Pregnancy. The Zepbound, Foundayo and Saxenda labels say to discontinue when a pregnancy is recognized. The Wegovy label says the same for patients using it for weight reduction. The semaglutide labels (Wegovy, Ozempic, Rybelsus) also say to discontinue at least 2 months before a planned pregnancy. See pregnancy and breastfeeding.
Suspected pancreatitis. The warnings in our side-effect records say the medicine should be discontinued if pancreatitis (inflammation of the pancreas) is suspected.
A serious allergic reaction. The warnings say to discontinue if a hypersensitivity reaction occurs and to seek medical attention promptly.
Lack of effect (Saxenda only). The Saxenda label tells prescribers to check the change in body weight 16 weeks after starting, and to discontinue if an adult has not lost at least 4% of baseline body weight (their weight at the start). Our dose records also note that Saxenda is discontinued if an adult can’t tolerate the 3 mg dose.
A switch to another GLP-1. The labels don’t recommend taking two of these medicines together, so one is stopped when another starts. That’s a planned change, covered in the switching guide.
On surgery, the warnings say to tell your healthcare providers that you take the medicine before any planned surgery or procedure. The decision is theirs.
What happens to weight after stopping?
Two labels in our records include a randomized withdrawal trial. In this kind of trial, everyone takes the medicine first, and then some are randomly switched to placebo (a dummy treatment).
Zepbound (Study 4)
All patients took Zepbound for 36 weeks, knowing what they were taking. They were then randomly assigned to keep taking it or switch to placebo for 52 weeks.
- After the 36-week lead-in, randomized patients had lost an average of 20.9% of body weight.
- From week 36 to week 88, body weight rose 14.0% in the group switched to placebo.
- It fell a further 5.5% in the group that kept taking Zepbound.
- At week 88, the difference between the groups was -19.4%.
Wegovy (Study 5)
The Wegovy injection dose was stepped up over a 20-week run-in. Patients who reached 2.4 mg weekly were then randomly assigned to keep taking Wegovy or switch to placebo for 48 weeks.
- From week 20 to week 68, body weight changed by +6.9% in the placebo group.
- It changed by -7.9% in the group that continued Wegovy.
- The difference was -14.8%.
The Wegovy label warns that people who stopped during titration, or who didn’t reach 2.4 mg, couldn’t enter the randomized period. So the results may not reflect the experience of people first starting Wegovy.
What these trials do and do not show
These are averages from two specific groups. They don’t predict what happens to any one person. They also don’t compare the two medicines, because the trials differ in length and design.
The maintenance guide describes the Saxenda weight-maintenance study, which has a different design.
Do you need to taper?
A taper means lowering the dose step by step before stopping. In both withdrawal trials above, patients were switched to placebo at randomization. If you and your prescriber decide you’ll stop, ask how they want it done.
Restarting after a gap
This is where the labels get most specific. The three products with a restart rule work differently from the rest.
Labels with a restart rule
- Wegovy injection. If 2 or more consecutive doses are missed, reinitiate dosage escalation at a lower dosage. That means stepping up again from a lower dose. Our switching record notes that the label doesn’t say which lower dosage, and that it gives no restart rule for Wegovy tablets.
- Foundayo. If 7 or more consecutive daily doses are missed, reinitiate dosage escalation at a lower dosage. Here too, the label doesn’t say which one.
- Saxenda. If more than 3 days have passed since the last dose, reinitiate at 0.6 mg daily and follow the escalation schedule again. This is the only one of the three that names the dose to restart at.
In each case, the label’s stated reason is to reduce the risk of gastrointestinal adverse reactions (stomach and gut side effects).
Labels with a missed dose rule only
For the other products, the label rule covers a single missed dose:
- Zepbound and Mounjaro: take the missed dose within 4 days (96 hours). After that, skip it and take the next dose on the regularly scheduled day.
- Ozempic injection: take it within 5 days. After that, skip it and take the next dose on the regularly scheduled day.
- Trulicity: take the missed dose if at least 3 days (72 hours) remain until the next scheduled dose. Otherwise skip it.
- Wegovy tablets, Ozempic tablets and Rybelsus: skip the missed dose and take the next dose the following day.
Each of these says patients can then go back to their regular schedule. None says what to do after several missed weeks. If you’ve been off Zepbound, Mounjaro, Ozempic or Trulicity for longer than one dose, ask your prescriber what dose to go back to before you take anything.
The missed dose calculator applies your label’s rule to your dates, and the missed dose rules page sets them side by side.
What a restart costs
Restarting at a lower dose means buying the lower strengths again and spending weeks below your previous dose. Our price records point to two things:
- Lower strengths can cost less per fill. A Zepbound 2.5 mg vial through LillyDirect is $299, against $449 at 15 mg.
- A gap can cost you the lower refill price. LillyDirect’s lower self-pay price on the higher Zepbound vial strengths requires a refill within 45 days. After a lapse, a 10 mg vial is $699 instead of $449. The 45-day rule page explains how the window works.
If cost is why you’re thinking about stopping, the cheapest path tool ranks the legitimate routes for your medicine, and the appeal letter tool helps if your coverage was denied. Unused pens go in a sharps container: see sharps disposal.
Frequently asked questions
What happens if you stop taking Zepbound?
The label's Study 4 measured it. After 36 weeks on Zepbound, patients had lost an average of 20.9% of body weight. In those then switched to placebo, body weight rose 14.0% over the next 52 weeks. Those who kept taking Zepbound lost a further 5.5%. These are trial averages, not a prediction for any one person.
Do you have to taper off Wegovy or Zepbound?
In the withdrawal trials on the Zepbound and Wegovy labels, patients were switched from the medicine to placebo. How to come off the medicine in your case is a question for your prescriber, so bring it up before your supply runs out.
Can I restart Wegovy at the same dose after a break?
Not after a longer gap, according to the label. If 2 or more consecutive doses of Wegovy injection are missed, the label says to reinitiate dosage escalation at a lower dosage to reduce the risk of gastrointestinal adverse reactions. In plain terms, you step up again from a lower dose. The label doesn't say which one, so your prescriber decides where you restart.
How long can I go without Zepbound before I have to restart?
The label's missed dose rule covers a single dose: take it within 4 days (96 hours), or skip it and take the next dose on the regular day. It doesn't say what to do after several missed weeks. Ask your prescriber before you take a dose after a long gap.
When does a label say to stop a GLP-1?
The labels in our records say to discontinue when a pregnancy is recognized (the weight-management products), if pancreatitis (inflammation of the pancreas) is suspected, and if a serious hypersensitivity (allergic) reaction occurs. The Saxenda label adds a rule for lack of effect: discontinue if an adult has not lost at least 4% of baseline body weight 16 weeks after starting.
Sources (23)
- 1.Wegovy prescribing information, section 2.4 Recommendations Regarding Missed Dose(s)
“If 2 or more consecutive doses of WEGOVY injection are missed, reinitiate dosage escalation at a lower dosage to reduce the risk of gastrointestinal adverse reactions [see Dosage and Administration (2.2), Warnings and Precautions (5.6), Adverse Reactions (6.1)].”
- 2.Foundayo prescribing information, section 2.3 Recommendations Regarding Missed Dose
“If 7 or more consecutive doses are missed, reinitiate dosage escalation at a lower dosage to reduce the risk of gastrointestinal adverse reactions [see Dosage and Administration (2.1), Warnings and Precautions (5.3), Adverse Reactions (6)].”
- 3.Saxenda prescribing information, section 2.1 Important Administration Instructions
“If more than 3 days have elapsed since the last SAXENDA dosage, reinitiate SAXENDA at 0.6 mg daily and follow the dosage escalation schedule in Table 1, to reduce the risk of gastrointestinal adverse reactions associated with reinitiation of treatment.”
- 4.Zepbound prescribing information, missed dose
“If more than 4 days have passed, skip the missed dose and administer the next dose on the regularly scheduled day. In each case, patients can then resume their regular once weekly dosing schedule.”
- 5.Ozempic prescribing information, missed dose
“If more than 5 days have passed, skip the missed dose and administer the next dose on the regularly scheduled day. In each case, patients can then resume their regular once-weekly dosing schedule.”
- 6.FDA label (DailyMed): Zepbound prescribing information, section 14.1
“Study 4 (NCT04660643) was an 88-week randomized withdrawal trial in which all patients received open-label ZEPBOUND during a 36-week lead-in period, followed by randomization to either continue ZEPBOUND or switch to placebo for 52 weeks.”
- 7.FDA label (DailyMed): Zepbound prescribing information, section 14.1
“After open-label ZEPBOUND treatment, randomized patients (n=670) had an average body weight loss of 20.9% (Week 0 to Week 36).”
- 8.FDA label (DailyMed): Zepbound prescribing information, section 14.1, Table 6
“Table 6: Changes in Body Weight After 36-Week Open-Label Treatment Followed by Randomized Withdrawal (Study 4) in Patients with Obesity or Overweight. % change from Week 36 at Week 88: Placebo N=335: 14.0; ZEPBOUND (MTD 10 mg or 15 mg) N=335: -5.5”
- 9.FDA label (DailyMed): Zepbound prescribing information, section 14.1, Table 6
“Table 6: Changes in Body Weight After 36-Week Open-Label Treatment Followed by Randomized Withdrawal (Study 4) in Patients with Obesity or Overweight. % difference from placebo at Week 88 (95% CI): ZEPBOUND (MTD 10 mg or 15 mg) N=335: -19.4 (-21.2, -17.7)”
- 10.FDA label (DailyMed): Wegovy prescribing information, section 14.2
“In Study 5 (NCT#03548987), WEGOVY injection was escalated during a 20-week run-in period, and patients who reached a WEGOVY 2.4 mg subcutaneous injection weekly dosage after the run-in period were randomized to either continued treatment with WEGOVY injection or placebo for 48 weeks.”
- 11.FDA label (DailyMed): Wegovy prescribing information, section 14.2, Table 9
“From randomization (week 20) to Week 68, treatment with WEGOVY injection resulted in a statistically significant reduction in body weight compared with placebo (Table 9).”
- 12.FDA label (DailyMed): Wegovy prescribing information, section 14.2
“Because patients who discontinued WEGOVY injection during titration and those who did not reach the 2.4 mg weekly dose were not eligible for the randomized-treatment period, the results may not reflect the experience of patients in the general population who are first starting WEGOVY injection.”
- 13.FDA label (DailyMed): Wegovy prescribing information, section 8.3
“Because of the potential for fetal harm, discontinue WEGOVY in patients at least 2 months before they plan to become pregnant to account for the long half-life of semaglutide”
- 14.FDA label (DailyMed): Wegovy prescribing information, section 8.1
“Weight loss offers no benefit to a pregnant patient and may cause fetal harm. When a pregnancy is recognized, advise the pregnant patient of the risk to a fetus. Discontinue WEGOVY in pregnant patients who are using it for weight reduction”
- 15.FDA label (DailyMed): Wegovy prescribing information, section 2.5
“One week after discontinuing WEGOVY 2.4 mg injection, initiate 25 mg of WEGOVY tablets orally once daily.”
- 16.FDA label (DailyMed): Wegovy prescribing information, section 2.5
“The day after discontinuing WEGOVY tablets 25 mg once daily, initiate WEGOVY 2.4 mg subcutaneous injection once weekly.”
- 17.FDA label (DailyMed): Ozempic prescribing information, section 8.3
“Discontinue OZEMPIC in women at least 2 months before a planned pregnancy due to the long washout period for semaglutide”
- 18.FDA label (DailyMed): Rybelsus and Ozempic tablets prescribing information, section 8.3
“Discontinue RYBELSUS or OZEMPIC tablets in women at least 2 months before a planned pregnancy due to the long washout period for semaglutide”
- 19.FDA label (DailyMed): Zepbound prescribing information, section 8.1
“Weight loss offers no benefit to a pregnant patient and may cause fetal harm. Advise pregnant patients that weight loss is not recommended during pregnancy and to discontinue ZEPBOUND when a pregnancy is recognized (see Clinical Considerations).”
- 20.FDA label (DailyMed): Foundayo prescribing information, section 8.1
“Weight loss offers no benefit to a pregnant patient and may cause fetal harm. When a pregnancy is recognized, advise the pregnant patient of the risk to a fetus and discontinue FOUNDAYO.”
- 21.FDA label (DailyMed): Saxenda prescribing information, section 8.1
“Additionally, weight loss offers no benefit to a pregnant patient and may cause fetal harm. When a pregnancy is recognized, advise the pregnant patient of the risk to a fetus, and discontinue SAXENDA”
- 22.FDA label (DailyMed): Saxenda prescribing information, section 2.2
“Evaluate the change in body weight 16 weeks after initiating SAXENDA and discontinue SAXENDA if the patient has not lost at least 4% of baseline body weight, since it is unlikely that the patient will achieve and sustain clinically meaningful weight loss with continued treatment.”
- 23.
Related pages
- Zepbound maintenance dose after goal weight: what the labels say about long-term use
- Missed dose of Ozempic, Zepbound or Wegovy: the label rule for every GLP-1
- GLP-1s, pregnancy and breastfeeding: what each label says
- Switching GLP-1 medications: what the labels say
- What is Zepbound? Uses, cost, doses and side effects
- What is Wegovy? Uses, doses, pill and pen, and cost
